TransMedics Acquires XVIVO Organ Care System Assets
Ticker: TMDX · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1756262
| Field | Detail |
|---|---|
| Company | Transmedics Group, Inc. (TMDX) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $12.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, assets, medical-devices
TL;DR
TransMedics just bought XVIVO's OCS assets, beefing up their transplant tech game.
AI Summary
TransMedics Group, Inc. announced on March 8, 2024, the completion of its acquisition of certain assets related to the Organ Care System (OCS) business from XVIVO Perfusion AB. This strategic move is expected to enhance TransMedics' position in the organ transplant market.
Why It Matters
This acquisition strengthens TransMedics' portfolio in the organ transplant technology sector, potentially leading to expanded market reach and improved patient outcomes.
Risk Assessment
Risk Level: medium — The integration of acquired assets carries inherent risks, and the financial impact on TransMedics will depend on the success of this integration and market reception.
Key Players & Entities
- TransMedics Group, Inc. (company) — Registrant
- XVIVO Perfusion AB (company) — Seller of acquired assets
- Organ Care System (OCS) (company) — Acquired business line
- March 8, 2024 (date) — Date of earliest event reported
- 200 Minuteman Road Andover, Massachusetts 01810 (location) — Principal Executive Offices
FAQ
What specific assets were acquired from XVIVO Perfusion AB?
The filing states that certain assets related to the Organ Care System (OCS) business were acquired. Specific details of the assets are not enumerated in this report.
What is the significance of the Organ Care System (OCS) to TransMedics?
The OCS is a business line that TransMedics has acquired, indicating its strategic importance to the company's operations and market position in organ transplantation.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated March 8, 2024.
What is TransMedics Group, Inc.'s principal executive office address?
The principal executive offices are located at 200 Minuteman Road, Andover, Massachusetts 01810.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 14.2 · Accepted 2024-03-12 16:05:57
Key Financial Figures
- $12.5 million — C for a purchase price of approximately $12.5 million (together with the Prior Acquisitions,
Filing Documents
- d723839d8k.htm (8-K) — 23KB
- 0001193125-24-065858.txt ( ) — 138KB
- tmdx-20240308.xsd (EX-101.SCH) — 3KB
- tmdx-20240308_lab.xml (EX-101.LAB) — 17KB
- tmdx-20240308_pre.xml (EX-101.PRE) — 11KB
- d723839d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSMEDICS GROUP, INC. Date: March 12, 2024 By: /s/ Stephen Gordon Name: Stephen Gordon Title: Chief Financial Officer and Treasurer